Findings from the DISCOVER-1 and DISCOVER-2 trials suggest that the interleukin-23 inhibitor guselkumab may be a promising treatment option for people with psoriatic arthritis.
Adjustment of infliximab dosing based on serum tumor necrosis factor-α levels has no impact on rates of remission and sustained treatment discontinuation among patients with rheumatoid arthritis, indicate results from the RRRR trial.
Results of a meta-analysis suggest that treatment with interleukin inhibitors may be associated with an increased risk for infections and cancer among people with rheumatic diseases.
A systematic review has identified insufficient representation of people from racial minority groups, older individuals, and men in randomized controlled trials investigating treatments for rheumatoid arthritis.
Addition of the Bruton’s tyrosine kinase inhibitor fenebrutinib to standard care does not improve outcomes for patients with systemic lupus erythematosus, suggest findings from a phase II trial.
Telitacicept, a recombinant fusion protein targeting B-lymphocyte stimulator and the APRIL proliferation-inducing ligand, has shown potential for the treatment of systemic lupus erythematosus in a phase IIb trial conducted in China.
Follow medwireNews